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Strengths and limitations of this study
 ► The longitudinal design of the study and collection of 
sequential samples from single patients allow us to 
capture biomarker changes associated with critical 
events during biological treatment.
 ► Integration of clinical data with data obtained from 
multiple types of biological material enables multio-
mics analysis for addressing the multifaceted nature 
of inflammatory bowel diseases.
 ► The long duration of follow- up also increases the 
likelihood that biomarker changes associated with 
degenerative changes in the intestines will be detect-
ed, which in turn could contribute to the discovery of 
novel molecular pathways and allow for therapeutic 
manipulation to halt disease progression.
 ► Missing data are expected in some patients as all 
samples are collected in relation to routine visits and 
routine sampling, especially intestinal tissue sam-
ples at baseline, are expected to be missing in some 
patients.
 ► Patient recruitment is limited by the actual rate of 
initiation of biological therapy in the clinical setting 
due to the observational design and the duration of 
follow- up will be limited (to 1 year only) in patients 
recruited during the last year of inclusion period.
AbStrACt
Introduction Inflammatory bowel diseases (IBDs) are 
chronic diseases of unknown cause characterised by a 
progressive and unpredictable disease course. In the last 
decade, biological treatment has become a cornerstone 
in the treatment of IBD. However, one- in- three- to- 
four patients do not respond to first- line biological 
agents and another third of patients see their response 
diminish over time. This highlights an unmet need for 
optimising the use of biologicals and the prediction of 
treatment response. Considering the multifaceted nature 
of IBD, we hypothesise that multiomics profiling of 
sequential samples from single patients could facilitate 
the discovery of predictive biomarkers of response to 
biological therapy and disease course.
Methods This is a multicentre prospective cohort 
study which will enrol 840 biological- naïve patients 
with IBD who initiate biological therapy in a 3- year 
period. Primary outcomes are the occurrence of primary 
non- response (evaluated at weeks 14–16) and loss of 
response (evaluated during entire follow- up in patients 
who obtain partial or full response after induction 
period). Each patient will be followed up for their clinical 
data for at least 1 year or till the end of study period (up 
to 4 years). Blood and stool samples will be collected 
sequentially during the first year of biological treatment. 
Intestinal tissue will be sampled after 1 year of treatment 
and whenever an endoscopy is performed. Samples will 
undergo transcriptomic, proteomic and microbial DNA 
analyses. Omics data will be integrated with clinical data 
to identify a panel of predictive biomarkers of response 
to biological therapy and disease behaviour in patients 
with IBD.
Ethics and dissemination Ethical approval has 
been obtained from the Danish Ethics Committee 
(H-18064178). Inclusion is ongoing at three study 
centres and will be initiated in two additional centres. 
Both positive and negative study results will be 
disseminated through peer- reviewed journals according 
to Strengthening the Reporting of Observational Studies 
in Epidemiology guidelines, as well as presented at 
international conferences.
IntroduCtIon
The number of people affected by inflam-
matory bowel diseases (IBDs) continues to 
increase globally, affecting up to 0.5% of 
the population worldwide.1 2 In Denmark 
alone, the prevalence of IBD in Denmark is 
estimated to be 52 730 and the incidence of 
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IBD has approached 25.9 per 100 000 person years and 
is steadily increasing.3 IBD, comprising ulcerative colitis 
(UC), Crohn’s disease (CD) and inflammatory bowel 
disease unclassified (IBDU) are complex, immune- 
mediated diseases characterised by chronic recurring 
inflammation in the gastrointestinal tract. Patients are 
often affected in their early adolescence and present 
with diarrhoea, abdominal pain and cramps, perianal 
complications, as well as systemic symptoms such as fever, 
fatigue, joint pain and weight loss. The unpredictable 
and progressive disease course of IBD not only impairs 
the patients’ quality of life, but also constitutes a socio-
economic burden.4 The annual cost of treatment is esti-
mated to be €5.6 billion in Europe alone, which does not 
account for indirect costs related to sick leave and work 
disability.5 6
During the last two decades, biological agents have 
become a cornerstone in the treatment of severe or 
refractory cases of IBD to induce and maintain remis-
sion. Biological agents are molecules targeting inflam-
matory mediators which have been shown to play a key 
role in the gut inflammation in IBD and include anti- 
tumour- necrosis- factor- alpha antibodies, anti- integrin- 
alpha4- beta7 antibodies, anti- alpha4- integrin antibodies, 
anti- interleukin 12/23 antibodies and Janus- kinase inhib-
itors.7 Treatment with biological agents has been shown to 
effectively decrease the risk of surgery and rate of hospi-
talisation in patients with IBD.8 In a nationwide cohort 
study in Denmark, the proportion of patients with CD 
and UC exposed to biological therapy was 28% and 9%, 
respectively, and the annual cost of biological therapy was 
estimated to constitute €1.9 million.9 However, 30%–40% 
patients do not respond to biologics and an additional 
30% of patients experience a diminished response over 
time.10 11 These patients often undergo several shifts in 
treatment and are exposed to excessive risk of adverse 
effects. Since IBD progresses over time, insufficient 
disease control might lead to irreversible degenerative 
changes in the intestine and require salvage surgery.12 We 
are currently unable to identify patients who will experi-
ence poor treatment response, hence we are unable to 
tailor biological treatment to a given patient. Novel, but 
expensive, IBD treatment options are soon to be intro-
duced and, as such, the need for measures to predict and 
optimise treatment outcome will only increase.13 14
Recent studies of some of the more than 200 genes 
associated with IBD have shown how these genes lead in 
different ways to disruption of intestinal homeostasis and 
immunological tolerance with subsequent inflammation 
that is characteristic of IBD.15 16 Previous studies have 
primarily focused on linking genetic polymorphisms asso-
ciated with IBD to the response to biological treatment, 
however, associations are vague and suggest that other 
omics profiles are also implicated.17 18 Recent findings 
indicate that mucosal inflammatory patterns and serum 
cytokine profiles differ between responders and non- 
responders to biological treatment.19–22 Furthermore, 
interactions between host and gut microbiota play a 
pivotal role in IBD pathogenesis and should be taken into 
consideration when predicting treatment response.23 24 
Considering the complex nature of IBD, prediction of 
treatment response is therefore likely to require the inte-
gration of multiple factors including genetic, environ-
mental, microbial and immunological factors into a 
multiomics model, which on the other hand may explain 
the pathobiology behind severe IBD phenotypes and 
intestinal damage.
Here, we present the study protocol for a prospec-
tive multicentre cohort study in patients with IBD who 
are initiating biological treatment for the first time 
(biological- naïve patients). The Danish IBD Biobank 
Project aims to identify a panel of predictive biomarkers 
associated with treatment response and long- term 
outcomes to biological therapy in biological- naïve 
patients with IBD.
AIMS of thE Study
Primary objectives of this study are to
1. Identify microbial, proteomic and transcriptomic pre-
dictors of treatment outcomes to biological therapy in 
biological- naïve patients with IBD.
2. Identify microbial, proteomic and transcriptomic bio-
markers of disease progression and degenerative fea-
tures of IBD.
Secondary objectives are to
1. Investigate treatment outcomes for biological treat-
ment in biological- naïve patients with IBD in a real- life 
setting.
2. Evaluate adherence to national and international 
guidelines regarding initiation, follow- up and optimi-
sation of biological therapy.
MEthodS
Study design
This study is a multicentre, prospective cohort study which 
will investigate microbial, proteomic and transcriptomic 
predictors of treatment outcomes to biological therapy 
in biological- naive patients with IBD. Patient enrolment 
was initiated in May 2019 and is currently ongoing at four 
study centres, two additional study centres will initiate 
enrolment in medio 2020. Enrolment will continue until 
May 2022. The duration of follow- up of each patient will 
be at least 1 year from initiation of biological therapy 
or until May 2023. Clinical data and biological samples 
will be collected at each study visit during the first year. 
Study visits are scheduled prior to initiation of biological 
therapy and subsequently at routine visits for the adminis-
tration of biological therapy at the outpatient clinic after 
0, 2 and 6 weeks of treatment, and subsequently every 
second or third month. After the first year, clinical data 
will be updated at least every 6 months until the end of 
follow- up (figure 1).
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Figure 1 Study design of the Danish IBD Biobank Project.
Patient and public involvement
Patients were not involved in the process of refining 
the research question or the design of this study. In the 
future, the study aims at involving the Danish patient 
organisation for patients with IBD (Colitis and Crohn’s 
Association) in the design of future studies which may 
arise from the current study.
Setting
The Danish IBD Biobank Project is a collaboration 
between the departments of gastroenterology at six hospi-
tals including five university hospitals located in four out 
of five geographic regions in Denmark. These include the 
departments of gastroenterology at Hvidovre University 
Hospital, Herlev University Hospital, Aarhus University 
Hospital, Aalborg University Hospital, Odense University 
Hospital and the Hospital of Soenderjylland. Patients will 
be recruited from the outpatient clinic or when they are 
admitted to the hospital prior to the initiation of biolog-
ical therapy.
Apart from the included departments, the study aims 
to expand the collaboration with other Danish hospitals 
in the future.
Study population
Patients are eligible for inclusion if they are (1) diag-
nosed with IBD (UC, CD and IBDU) according to the 
Copenhagen diagnostic criteria,25 (2) aged 18 or above 
and (3) starting treatment with biological therapy due to 
IBD and have never received treatment with biological 
agents previously.
Initiation of biological treatment is a clinical decision 
made by the patient’s physician. Patients will receive 
biological therapy according to the guidelines and 
recommendations from the Danish Medicines Council, 
which include dosing and treatment intervals according 
to the drug labels. All participating hospitals are advised 
to follow the National Treatment Guidelines for biolog-
ical treatment of IBD patients issued by the Medicine 
Council,7 According to these guidelines, 80% of patients 
with CD initiating biological treatment due to luminal 
activity are expected to receive either (1) infliximab, (2) 
adalimumab or (3) vedolizumab as first- line or second- 
line treatment, all three drugs and ustekinumab may 
also be used as third- line or fourth- line treatment. These 
recommendations also apply to fistulising patients with 
CD except for the use of vedolizumab which is only 
approved as third- line or fourth- line treatment. In acutely 
severe UC, patients in need of ‘rescue’ treatment with 
biologicals will receive infliximab. In chronic active UC 
who will initiate biological therapy, 80% are expected 
to receive (1) infliximab, (2) vedolizumab or (3) goli-
mumab as first- line or second- line treatment, further-
more, tofacitinib may be used as second- line treatment, 
all above- mentioned drugs and adalimumab may also be 
used as third- line treatment.7 Furthermore, the study will 
include patients who initiate treatment with biological 
agents which might be approved in the future. There are 
no exclusion criteria in this study.
outcome measures
Clinical response and primary non- response (PNR) to 
biological therapy will be evaluated after the end of the 
induction period, at week 14 for infliximab and vedol-
izumab, and week 12 for adalimumab, golimumab, 
certolizumab, ustekinumab and tofacitinib. Endoscopic 
remission will be evaluated 12 months after the start of 
treatment. In patients who continue biological treatment 
in a maintenance regime after initially achieving a partial 
or full response, the proportion of patients with loss of 
response (LOR) will be registered after 6 and 12 months 
of biological treatment.
Clinical activity will be assessed using the Simple Clinical 
Colitis Activity Index (SCCAI)26 for UC and IBDU patients 
and the Harvey- Bradshaw Index (HBI)27 for patients with 
CD. Endoscopic activity will be assessed using the Ulcer-
ative Colitis Endoscopic Index of Severity (UCEIS)28 in 
UC and the Simple Endoscopic Score for Crohn’s Disease 
(SES- CD)29 in patients with CD. Radiological activity will 
be assessed in patients with CD who undergo imaging with 
MRI or abdominal CT using the Lemann Index, which 
indicates intestinal damage.30 The Lemann Index will be 
evaluated at the end of follow- up by a gastroenterologist, in 
collaboration with a radiologist, at each study centre.
Primary outcomes in this study are as follows:
1. PNR to treatment: defined as lack of clinical response 
with induction therapy defined as a decrease in SCCAI 
of ≥2 points from baseline in patients with UC31; or a 
decrease in HBI of >3 points from baseline in patients 
with CD,32 as well as patients who undergo intestinal 
resection or colectomy due to IBD, or as fistula revi-
sion in patients with perianal CD during the period of 
induction therapy.
2. LOR to treatment: defined as patients achieving clini-
cal response (as measured by clinical activity indices) 
during the period of induction therapy, but who later 
suffer from clinical relapse during maintenance thera-
py, including the need for rescue therapy with cortico-
steroids or an alternative biological therapy, or surgery 
for IBD.
Secondary outcomes in this study are as follows:
1. Clinical remission to treatment: defined as an SCCAI 
of ≤2 in patients with UC31; or an HBI of ≤4 in patients 
with CD.32
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Figure 2 Sample collection and storage in the Danish IBD 
Biobank project.
2. Endoscopic remission: defined as a UCEIS of ≤1 in pa-
tients with UC28; or an SES- CD of <4 in patients with 
CD.
3. Surgery: defined as intestinal resection or colectomy 
due to disease activity of IBD not responding to medi-
cal therapy, or as fistula revision or drainage of abscess-
es after initiation of biological therapy in patients with 
perianal CD.
Clinical data
At the time of inclusion, data on patient demographics 
(age, gender, ethnicity, education, height and body 
weight), disease characteristics (disease duration, disease 
phenotype including disease subtype, disease location, 
disease behaviour and extra- intestinal disease manifesta-
tions), medical history, history of surgery, family history 
of IBD, past and current medications, smoking status 
(current/former/never user; duration; amount), as well 
as dietary preferences, will be gathered from the patient’s 
medical record and by the use of a food frequency 
questionnaire.
During follow- up, information on clinical disease 
activity, disease phenotype, current medication, surgery, 
hospital admission, and development of comorbidity will 
be updated at each study visit during the first year and 
every 6 months thereafter. Furthermore, results from 
endoscopic procedures, imaging procedures, as well 
as results of routine blood samples (C reactive protein, 
leucocyte count, albumin, haemoglobin and therapeutic 
drug monitoring measurements) and faecal- calprotectin 
will be registered to evaluate mucosal healing and inflam-
matory burden at each of the aforementioned time 
points.
biological samples
Biological samples of blood, stool and intestinal tissue 
will be collected prospectively during the first year of 
follow- up. Blood and stool samples will be collected 
immediately prior to the initiation of biological therapy 
and subsequently at each visit for drug administration of 
biological therapy. On each blood sampling, a 9 mL EDTA 
tube and a 9 mL serum tube will be collected to yield 
plasma and buffy coat and serum, respectively. Further-
more, a 2.5 mL PAX- gene Blood Tube will be collected 
for later transcriptomics analysis. Stool samples will be 
collected using a faecal sample collection kit preserved 
with 96% ethanol or using a rectal foam dry swab to be 
immediately stored at −80°C after sample collection.
Intestinal tissue samples will be collected at each endo-
scopic procedure that the patient undergoes (unrelated 
to study participation) during follow- up and at an extra 
endoscopy after 1 year of follow- up. According to national 
guidelines, we expect an endoscopy to be performed at 
baseline, immediately before initiation of biological 
therapy, on change of treatment, and at least once per 
year while the patient receives biological treatment. Intes-
tinal tissue samples will be collected from predefined 
locations: in patients with CD, biopsies will be taken from 
terminal ileum, ascending and sigmoid colon; in patients 
with UC, biopsies will be taken from the ascending and 
sigmoid colon, as well as the rectum. Two samples will be 
collected from each location, one sample will be treated 
with RNA- later and handled according to instructions 
from the product company, while the other sample 
will be snap frozen in liquid nitrogen. In addition, two 
samples will be collected from any additional area of 
inflammation.
All biological samples will be stored at −80°C until they 
are analysed (figure 2).
data management
Clinical data will be collected using an electronic case 
report form (eCRF) based on the electronic data capture 
system, Research Electronic Data Capture (REDCap), 
a tool designed to support data capture for research 
studies.33 REDCap provides validated data entry and 
audit trails as well as anonymised data import and export. 
Appointed staff members at each study centre have autho-
rised access to study data, roles in the system are given 
according to functions and all access to the server and 
other server maintenances will be logged. Study set- up 
and hosting are performed by a PhD student at Hvidovre 
University Hospital. Authorised staff members (one PhD 
student, one student research assistant, two physicians) 
can add data to the electronic database and will keep the 
database current to reflect subject status during the study 
period. Once the eCRF for a subject is completed, the 
project personnel at each local centre will approve the 
data using an electronic signature and thereby confirm 
the accuracy of the data recorded. Biological samples 
will be stored at −80°C until analysis of the samples in 
batch runs. All data will be stored confidentially in locked 
freezers located in locked rooms which are only acces-
sible to authorised staff.
On study termination, electronic data will be stored for 
an additional 10 years before deletion. Biological data will 
be transferred to a biobank for future research hosted at 
a centrally regulated biobank facility driven by the Capital 
Region of Denmark, this has been approved by the Data 
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Regulatory Agency and consent from the participants will 
be sought on recruitment. In order to maintain respon-
sible data sharing and to keep patient data confidentially, 
data collected in the study will not be shared as an open- 
access resource; however, researchers are welcome to 
apply for access to the biobank material for future proj-
ects by contacting the steering group of the project. In 
Denmark, collaboration with external research partners 
requires separate approval from the Data Regulation 
Agency and the establishment of a specific data processing 
agreement; therefore, data sharing with external part-
ners will be decided on a case- by- case basis in the steering 
group.
AnAlySIS PlAn
Sample size calculation
Each centre is expected to start biological therapy in 5–6 
biological- naïve patients with IBD per month, resulting in 
a total of 840 patients across 3 years. At least 30% of these 
are expected to be either PNRs or LORs, corresponding 
to 252 patients. Biological samples from 200 patients with 
PNR and LOR and 70 responders will undergo primary 
analysis. The sample size has been calculated to be able 
to detect a 1.3- fold upregulation of relevant genes with 
a common standard deviation (sigma) of one and the 
desired power of 80% to determine a statistically signif-
icant difference (α=0.05, two- sided test). The estimated 
sample size is 197 subjects in the PNR/LOR group and 66 
subjects in the responder group.
Analysis of biological samples
Blood and tissue samples will undergo a transcriptomic 
analysis. RNA quality will be determined by a Bioanalyzer 
and RNA integrity numbers will be calculated. RNA and 
miRNA expression profiles will be determined using 
microarray and high- throughput parallel sequencing 
(Illumina) to provide a global gene expression pattern 
using bioinformatics- based computational methods. Key 
pathways will be extracted by in silico annotation anal-
ysis of the transcriptome data. PCR analysis, Western 
blotting and immunohistochemistry will subsequently be 
used to confirm expression patterns of interest. Serum 
and plasma will undergo characterisation of preselected 
serum and plasma proteins using inflammation assays.
Stool samples will undergo analysis for microbiota and 
purification of microbiome DNA will be performed as 
described by Yan et al.34 Samples will undergo 16S and 
18S PCR (examining bacteria, fungi and parasites) and 
Illumina sequencing and annotation of DNA sequences 
to species level. Data will thereafter be run in in- house 
R- scripts, which will identify both quantitative and quali-
tative differences in microbiota between cohorts.
Statistical analysis
Statistical programming will be carried out using the 
software R or SPSS Statistics Version 26. Details of the 
statistical analyses will be provided in the statistical 
analysis plan, which will be finished before data collec-
tion is completed. Comparison of demographics between 
patient groups will be performed using the χ² test for 
nominal variables and t- test or Mann- Whitney U test for 
ordinal variables, according to data distribution. Logistic 
and Cox regression models will be performed to find 
potential correlations between baseline characteristics 
and treatment outcome. Univariate and multivariate hier-
archical clustering and principal component analysis will 
be applied to identify a panel of biomarkers which differ-
entiate between patient groups according to their treat-
ment response. Receiver operator characteristic analyses 
will be performed to evaluate the sensitivity and speci-
ficity of single biomarkers and the composite biomarker 
panel. Biomarkers which are correlated to treatment 
response will later be assessed in a validation cohort using 
logistic regression and adjusted for covariates such as age, 
gender, disease phenotype and concomitant treatment. 
Statisticians and bio- informaticians will be consulted for 
their statistical expertise.
CurrEnt StAtuS
The project has been initiated in May 2019 and is currently 
ongoing at three study centres. A total of 160 patients 
have been recruited over a period of 7 months; the 
current recruitment rate is higher than estimated (105–
126 patients). One study centre has initiated recruitment 
in January 2020 and two other study centres are expected 
to initiate recruitment in medio 2020.
dISCuSSIon And ExPECtEd lIMItAtIonS
A major strength of this project is its longitudinal design. 
The building of a biobank with sequential samples from 
single patients at different time points during biological 
treatment allows us to observe biomarker changes asso-
ciated with critical events, including LOR to specific 
biological agents and disease progression. The extensive 
collection of data, including clinical data, laboratory data, 
as well as multiple types of biological material, allows us 
to perform multiomics analyses that will take into account 
the complex interplay between host genome and host 
immune responses on the one hand, and gut microbes 
and environmental exposures on the other. In this way, 
we will seek to identify a panel of serological, faecal and 
mucosal biomarkers which might assist physicians in 
tailoring biological treatment to the individual patient 
with IBD. The long duration of follow- up also allows us to 
study biological patterns which are associated with disease 
progression in IBD and the development of degenerative 
changes in the intestines. We thereby hope to facilitate 
the discovery of molecular pathways which might allow 
for therapeutic manipulation to halt disease progression 
in patients with IBD.
The study does have some limitations to address. All 
tissue samples will be collected as part of routine endosco-
pies, apart from one supplementary endoscopy scheduled 
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at 1 year after initiation of biological treatment. Despite 
national guidelines recommending that an endoscopy 
take place prior to initiation of biological treatment, 
tissue samples at baseline will inevitably be missing in 
some patients, since an endoscopy prior to treatment 
initiation will not be performed in all patients in clinical 
practice. Similarly, blood and stool samples are collected 
as part of routine sampling at regular visits, and this might 
challenge data comprehensiveness in some patients, for 
instance those lost during follow- up. All study centres also 
engage in randomised trials with experimental biolog-
ical agents in patients with IBD, and so we expect some 
patients to be excluded due to participation in alternative 
trials; however, this number is expected to be small. At 
last, the enrolment rate will depend on the number of 
incident biological users initiating biological therapy in 
the clinical setting due to the observational study design. 
However, to date, the rate of enrolment has exceeded the 
anticipated rate and the enrolment target is evaluated as 
feasible.
dissemination of results
Study results will be published according to the Strength-
ening the Reporting of Observational Studies in Epidemi-
ology guidelines. Both negative and positive results from 
the study will be published. Results will be submitted to 
publication in international peer- reviewed scientific jour-
nals and presented at scientific conferences. The national 
patient organisation for patients with IBDs (the Danish 
Colitis and Crohn’s Organization) will be involved to 
help develop the dissemination strategy and to share 
study results with patients. Patients who participate in the 
project will be informed by letter of the study results if 
they express interest in this on study entry. Furthermore, 
study results and publications will be made public on the 
project website ( www. ibdbiobank. com).
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